Search

Your search keyword '"Allen, Joshua E."' showing total 644 results
Start Over Author "Allen, Joshua E."
644 results on '"Allen, Joshua E."'

2. Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors

Author

Ellingson, Benjamin M, Gerstner, Elizabeth R, Lassman, Andrew B, Chung, Caroline, Colman, Howard, Cole, Patricia E, Leung, David, Allen, Joshua E, Ahluwalia, Manmeet S, Boxerman, Jerrold, Brown, Matthew, Goldin, Jonathan, Nduom, Edjah, Hassan, Islam, Gilbert, Mark R, Mellinghoff, Ingo K, Weller, Michael, Chang, Susan, Arons, David, Meehan, Clair, Selig, Wendy, Tanner, Kirk, Yung, WK Alfred, van den Bent, Martin, Wen, Patrick Y, and Cloughesy, Timothy F

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Neurosciences, Rare Diseases, Brain Cancer, Brain Disorders, Cancer, Biomedical Imaging, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Neurological, Brain Neoplasms, Clinical Trials as Topic, Diagnostic Imaging, Humans, Treatment Outcome, response assessment, brain tumors, clinical trials, growth rates, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Imaging response assessment is a cornerstone of patient care and drug development in oncology. Clinicians/clinical researchers rely on tumor imaging to estimate the impact of new treatments and guide decision making for patients and candidate therapies. This is important in brain cancer, where associations between tumor size/growth and emerging neurological deficits are strong. Accurately measuring the impact of a new therapy on tumor growth early in clinical development, where patient numbers are small, would be valuable for decision making regarding late-stage development activation. Current attempts to measure the impact of a new therapy have limited influence on clinical development, as determination of progression, stability or response does not currently account for individual tumor growth kinetics prior to the initiation of experimental therapies. Therefore, we posit that imaging-based response assessment, often used as a tool for estimating clinical effect, is incomplete as it does not adequately account for growth trajectories or biological characteristics of tumors prior to the introduction of an investigational agent. Here, we propose modifications to the existing framework for evaluating imaging assessment in primary brain tumors that will provide a more reliable understanding of treatment effects. Measuring tumor growth trajectories prior to a given intervention may allow us to more confidently conclude whether there is an anti-tumor effect. This updated approach to imaging-based tumor response assessment is intended to improve our ability to select candidate therapies for later-stage development, including those that may not meet currently sought thresholds for "response" and ultimately lead to identification of effective treatments.

Published
2022

3. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma

Author

He, Ling, Bhat, Kruttika, Ioannidis, Angeliki, Zhang, Le, Nguyen, Nhan T, Allen, Joshua E, Nghiemphu, Phioanh Leia, Cloughesy, Timothy F, Liau, Linda M, Kornblum, Harley I, and Pajonk, Frank

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Genetics, Rare Diseases, Radiation Oncology, Stem Cell Research - Nonembryonic - Human, Biotechnology, Orphan Drug, Neurosciences, Brain Disorders, Human Genome, Stem Cell Research, Brain Cancer, 5.1 Pharmaceuticals, Adult, Animals, Brain Neoplasms, Cell Line, Tumor, Glioblastoma, Humans, Imidazoles, Mice, Neoplasm Recurrence, Local, Pyridines, Pyrimidines, Receptors, Dopamine D2, Xenograft Model Antitumor Assays, Radiotherapy, Dopamine receptor antagonist, Transcriptome analyses, Quiescent glioblastoma cells, Other Physical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Medical and biological physics
Abstract

BackgroundGlioblastoma (GBM) is the deadliest of all brain cancers in adults. The current standard-of-care is surgery followed by radiotherapy and temozolomide, leading to a median survival time of only 15 months. GBM are organized hierarchically with a small number of glioma-initiating cells (GICs), responsible for therapy resistance and tumor recurrence, suggesting that targeting GICs could improve treatment response. ONC201 is a first-in-class anti-tumor agent with clinical efficacy in some forms of high-grade gliomas. Here we test its efficacy against GBM in combination with radiation.MethodsUsing patient-derived GBM lines and mouse models of GBM we test the effects of radiation and ONC201 on GBM self-renewalin vitro and survivalin vivo.A possible resistance mechanism is investigated using RNA-Sequencing.ResultsTreatment of GBM cells with ONC201 reduced self-renewal, clonogenicity and cell viabilityin vitro. ONC201 exhibited anti-tumor effects on radioresistant GBM cells indicated by reduced self-renewal in secondary and tertiary glioma spheres. Combined treatment of ONC201 and radiation prolonged survival in syngeneic and patient-derived orthotopic xenograft mouse models of GBM. Subsequent transcriptome analyses after combined treatment revealed shifts in gene expression signatures related to quiescent GBM populations, GBM plasticity, and GBM stem cells.ConclusionsOur findings suggest that combined treatment with the DRD2/3 antagonist ONC201 and radiation improves the efficacy of radiation against GBMin vitroandin vivothrough suppression of GICs without increasing toxicity in mouse models of GBM. A clinical assessment of this novel combination therapy against GBM is further warranted.

Published
2021

5. The imipridone ONC213 targets OGDH to kill acute myeloid leukemia cells

Author

Fukuda, Yu, primary, Su, Yongwei, additional, Carter, Jenna L., additional, Gray, Ashley, additional, Lynch, John, additional, Edwards, Holly, additional, Schreiner, Patrick, additional, Polin, Lisa, additional, Pruett-Miller, Shondra M., additional, Li, Jing, additional, Allen, Joshua E., additional, Prabhu, Varun V., additional, Schimmer, Aaron D., additional, Taub, Jeffrey W., additional, Schuetz, John, additional, and Ge, Yubin, additional

Published
2024
Full Text
View/download PDF

6. Supplementary Methods from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

7. Figure S7 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

8. Table S1 from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Data - THP-1 metabolomics from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Data - MV4-11 metabolomics from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

11. Data from The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., primary, Li, Xinyu, primary, Fukuda, Yu, primary, Gray, Ashley, primary, Lynch, John, primary, Edwards, Holly, primary, Ma, Jun, primary, Schreiner, Patrick, primary, Polin, Lisa, primary, Kushner, Juiwanna, primary, Dzinic, Sijana H., primary, Buck, Steven A., primary, Pruett-Miller, Shondra M., primary, Hege-Hurrish, Katie, primary, Robinson, Camenzind, primary, Qiao, Xinan, primary, Liu, Shuang, primary, Wu, Shuangshuang, primary, Wang, Guan, primary, Li, Jing, primary, Allen, Joshua E., primary, Prabhu, Varun V., primary, Schimmer, Aaron D., primary, Joshi, Dhananjay, primary, Kalhor-Monfared, Shiva, primary, Watson, Iain D. G., primary, Marcellus, Richard, primary, Isaac, Methvin B., primary, Al-awar, Rima, primary, Taub, Jeffrey W., primary, Lin, Hai, primary, Schuetz, John D., primary, and Ge, Yubin, primary

Published
2024
Full Text
View/download PDF

12. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

Author

de la Nava, Daniel, primary, Ausejo-Mauleon, Iker, additional, Laspidea, Virginia, additional, Gonzalez-Huarriz, Marisol, additional, Lacalle, Andrea, additional, Casares, Noelia, additional, Zalacain, Marta, additional, Marrodan, Lucía, additional, García-Moure, Marc, additional, Ochoa, Maria C, additional, Tallon-Cobos, Antonio Carlos, additional, Hernandez-Osuna, Reyes, additional, Marco-Sanz, Javier, additional, Dhandapani, Laasya, additional, Hervás-Corpión, Irati, additional, Becher, Oren J, additional, Nazarian, Javad, additional, Mueller, Sabine, additional, Phoenix, Timothy N, additional, van der Lugt, Jasper, additional, Hernaez, Mikel, additional, Guruceaga, Elizabeth, additional, Koschmann, Carl, additional, Venneti, Sriram, additional, Allen, Joshua E, additional, Dun, Matthew D, additional, Fueyo, Juan, additional, Gomez-Manzano, Candelaria, additional, Perez-Larraya, Jaime Gallego, additional, Patiño-García, Ana, additional, Labiano, Sara, additional, and Alonso, Marta M, additional

Published
2024
Full Text
View/download PDF

13. ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Author

Arrillaga-Romany, Isabel, primary, Lassman, Andrew, additional, McGovern, Susan L, additional, Mueller, Sabine, additional, Nabors, Burt, additional, van den Bent, Martin, additional, Vogelbaum, Michael, additional, Allen, Joshua E, additional, Melemed, Allen S, additional, Tarapore, Rohinton S, additional, Wen, Patrick Y, additional, and Cloughesy, Timothy, additional

Published
2024
Full Text
View/download PDF

16. ACTION:a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Author

Arrillaga-Romany, Isabel, Lassman, Andrew, McGovern, Susan L., Mueller, Sabine, Nabors, Burt, van den Bent, Martin, Vogelbaum, Michael A., Allen, Joshua E., Melemed, Allen S., Tarapore, Rohinton S., Wen, Patrick Y., Cloughesy, Timothy, Arrillaga-Romany, Isabel, Lassman, Andrew, McGovern, Susan L., Mueller, Sabine, Nabors, Burt, van den Bent, Martin, Vogelbaum, Michael A., Allen, Joshua E., Melemed, Allen S., Tarapore, Rohinton S., Wen, Patrick Y., and Cloughesy, Timothy

Abstract

BACKGROUND: H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma.METHODS: ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on 2 consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS); PFS is assessed by response assessment in neuro-oncology high-grade glioma criteria (RANO-HGG) by blind independent central review. Secondary objectives include safety, additional efficacy endpoints, clinical benefit, and quality of life. Eligible patients have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility is not restricted by age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in multiple international sites.

Published
2024

17. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Author

Prabhu, Varun Vijay, Morrow, Sara, Rahman Kawakibi, Abed, Zhou, Lanlan, Ralff, Marie, Ray, Jocelyn, Jhaveri, Aakash, Ferrarini, Isacco, Lee, Young, Parker, Cassandra, Zhang, Yiqun, Borsuk, Robyn, Chang, Wen-I, Honeyman, Joshua N., Tavora, Fabio, Carneiro, Benedito, Raufi, Alexander, Huntington, Kelsey, Carlsen, Lindsey, Louie, Anna, Safran, Howard, Seyhan, Attila A., Tarapore, Rohinton S., Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, and El-Deiry, Wafik S.

Published
2020
Full Text
View/download PDF

18. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma

Author

Arrillaga-Romany, Isabel, primary, Gardner, Sharon L., additional, Odia, Yazmin, additional, Aguilera, Dolly, additional, Allen, Joshua E., additional, Batchelor, Tracy, additional, Butowski, Nicholas, additional, Chen, Clark, additional, Cloughesy, Timothy, additional, Cluster, Andrew, additional, de Groot, John, additional, Dixit, Karan S., additional, Graber, Jerome J., additional, Haggiagi, Aya M., additional, Harrison, Rebecca A., additional, Kheradpour, Albert, additional, Kilburn, Lindsay B., additional, Kurz, Sylvia C., additional, Lu, Guangrong, additional, MacDonald, Tobey J., additional, Mehta, Minesh, additional, Melemed, Allen S., additional, Nghiemphu, Phioanh Leia, additional, Ramage, Samuel C., additional, Shonka, Nicole, additional, Sumrall, Ashley, additional, Tarapore, Rohinton S., additional, Taylor, Lynne, additional, Umemura, Yoshie, additional, and Wen, Patrick Y., additional

Published
2024
Full Text
View/download PDF

19. The imipridone ONC213 targets α-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia

Author

Su, Yongwei, primary, Carter, Jenna L., additional, Li, Xinyu, additional, Fukuda, Yu, additional, Gray, Ashley, additional, Lynch, John, additional, Edwards, Holly, additional, Ma, Jun, additional, Schreiner, Patrick, additional, Polin, Lisa, additional, Kushner, Juiwanna, additional, Dzinic, Sijana H., additional, Buck, Steven A., additional, Pruett-Miller, Shondra M., additional, Hurrish, Katie Hege., additional, Robinson, Camenzind, additional, Qiao, Xinan, additional, Liu, Shuang, additional, Wu, Shuangshuang, additional, Wang, Guan, additional, Li, Jing, additional, Allen, Joshua E., additional, Prabhu, Varun V., additional, Schimmer, Aaron D., additional, Joshi, Dhananjay, additional, Kalhor-Monfared, Shiva, additional, Watson, Iain D. G., additional, Marcellus, Richard, additional, Isaac, Methvin B., additional, Al-awar, Rima, additional, Taub, Jeffrey W., additional, Lin, Hai, additional, Schuetz, John D., additional, and Ge, Yubin, additional

Published
2024
Full Text
View/download PDF

23. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

Author

Nii, Takenobu, Prabhu, Varun V., Ruvolo, Vivian, Madhukar, Neel, Zhao, Ran, Mu, Hong, Heese, Lauren, Nishida, Yuki, Kojima, Kensuke, Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Charter, Neil, Deacon, Sean, Elemento, Olivier, Allen, Joshua E., Oster, Wolfgang, Stogniew, Martin, Ishizawa, Jo, and Andreeff, Michael

Published
2019
Full Text
View/download PDF

25. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.

Author

Odia, Yazmin, Koschmann, Carl, Vitanza, Nicholas A, Blank, Peter de, Aguilera, Dolly, Allen, Jeffrey, Daghistani, Doured, Hall, Matthew, Khatib, Ziad, Kline, Cassie, MacDonald, Tobey, Mueller, Sabine, Faison, Shamia L, Allen, Joshua E, Naderer, Odin J, Ramage, Samuel C, Tarapore, Rohinton S, McGovern, Susan Lynne, Khatua, Soumen, and Zaky, Wafik

Published
2024
Full Text
View/download PDF

26. Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Author

Venneti, Sriram, primary, Kawakibi, Abed Rahman, primary, Ji, Sunjong, primary, Waszak, Sebastian M., primary, Sweha, Stefan R., primary, Mota, Mateus, primary, Pun, Matthew, primary, Deogharkar, Akash, primary, Chung, Chan, primary, Tarapore, Rohinton S., primary, Ramage, Samuel, primary, Chi, Andrew, primary, Wen, Patrick Y., primary, Arrillaga-Romany, Isabel, primary, Batchelor, Tracy T., primary, Butowski, Nicholas A., primary, Sumrall, Ashley, primary, Shonka, Nicole, primary, Harrison, Rebecca A., primary, de Groot, John, primary, Mehta, Minesh, primary, Hall, Matthew D., primary, Daghistani, Doured, primary, Cloughesy, Timothy F., primary, Ellingson, Benjamin M., primary, Beccaria, Kevin, primary, Varlet, Pascale, primary, Kim, Michelle M., primary, Umemura, Yoshie, primary, Garton, Hugh, primary, Franson, Andrea, primary, Schwartz, Jonathan, primary, Jain, Rajan, primary, Kachman, Maureen, primary, Baum, Heidi, primary, Burant, Charles F., primary, Mottl, Sophie L., primary, Cartaxo, Rodrigo T., primary, John, Vishal, primary, Messinger, Dana, primary, Qin, Tingting, primary, Peterson, Erik, primary, Sajjakulnukit, Peter, primary, Ravi, Karthik, primary, Waugh, Alyssa, primary, Walling, Dustin, primary, Ding, Yujie, primary, Xia, Ziyun, primary, Schwendeman, Anna, primary, Hawes, Debra, primary, Yang, Fusheng, primary, Judkins, Alexander R., primary, Wahl, Daniel, primary, Lyssiotis, Costas A., primary, de la Nava, Daniel, primary, Alonso, Marta M., primary, Eze, Augustine, primary, Spitzer, Jasper, primary, Schmidt, Susanne V., primary, Duchatel, Ryan J., primary, Dun, Matthew D., primary, Cain, Jason E., primary, Jiang, Li, primary, Stopka, Sylwia A., primary, Baquer, Gerard, primary, Regan, Michael S., primary, Filbin, Mariella G., primary, Agar, Nathalie Y.R., primary, Zhao, Lili, primary, Kumar-Sinha, Chandan, primary, Mody, Rajen, primary, Chinnaiyan, Arul, primary, Kurokawa, Ryo, primary, Pratt, Drew, primary, Yadav, Viveka N., primary, Grill, Jacques, primary, Kline, Cassie, primary, Mueller, Sabine, primary, Resnick, Adam, primary, Nazarian, Javad, primary, Allen, Joshua E., primary, Odia, Yazmin, primary, Gardner, Sharon L., primary, and Koschmann, Carl, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Author

Venneti, Sriram, primary, Kawakibi, Abed Rahman, primary, Ji, Sunjong, primary, Waszak, Sebastian M., primary, Sweha, Stefan R., primary, Mota, Mateus, primary, Pun, Matthew, primary, Deogharkar, Akash, primary, Chung, Chan, primary, Tarapore, Rohinton S., primary, Ramage, Samuel, primary, Chi, Andrew, primary, Wen, Patrick Y., primary, Arrillaga-Romany, Isabel, primary, Batchelor, Tracy T., primary, Butowski, Nicholas A., primary, Sumrall, Ashley, primary, Shonka, Nicole, primary, Harrison, Rebecca A., primary, de Groot, John, primary, Mehta, Minesh, primary, Hall, Matthew D., primary, Daghistani, Doured, primary, Cloughesy, Timothy F., primary, Ellingson, Benjamin M., primary, Beccaria, Kevin, primary, Varlet, Pascale, primary, Kim, Michelle M., primary, Umemura, Yoshie, primary, Garton, Hugh, primary, Franson, Andrea, primary, Schwartz, Jonathan, primary, Jain, Rajan, primary, Kachman, Maureen, primary, Baum, Heidi, primary, Burant, Charles F., primary, Mottl, Sophie L., primary, Cartaxo, Rodrigo T., primary, John, Vishal, primary, Messinger, Dana, primary, Qin, Tingting, primary, Peterson, Erik, primary, Sajjakulnukit, Peter, primary, Ravi, Karthik, primary, Waugh, Alyssa, primary, Walling, Dustin, primary, Ding, Yujie, primary, Xia, Ziyun, primary, Schwendeman, Anna, primary, Hawes, Debra, primary, Yang, Fusheng, primary, Judkins, Alexander R., primary, Wahl, Daniel, primary, Lyssiotis, Costas A., primary, de la Nava, Daniel, primary, Alonso, Marta M., primary, Eze, Augustine, primary, Spitzer, Jasper, primary, Schmidt, Susanne V., primary, Duchatel, Ryan J., primary, Dun, Matthew D., primary, Cain, Jason E., primary, Jiang, Li, primary, Stopka, Sylwia A., primary, Baquer, Gerard, primary, Regan, Michael S., primary, Filbin, Mariella G., primary, Agar, Nathalie Y.R., primary, Zhao, Lili, primary, Kumar-Sinha, Chandan, primary, Mody, Rajen, primary, Chinnaiyan, Arul, primary, Kurokawa, Ryo, primary, Pratt, Drew, primary, Yadav, Viveka N., primary, Grill, Jacques, primary, Kline, Cassie, primary, Mueller, Sabine, primary, Resnick, Adam, primary, Nazarian, Javad, primary, Allen, Joshua E., primary, Odia, Yazmin, primary, Gardner, Sharon L., primary, and Koschmann, Carl, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Author

Venneti, Sriram, primary, Kawakibi, Abed Rahman, primary, Ji, Sunjong, primary, Waszak, Sebastian M., primary, Sweha, Stefan R., primary, Mota, Mateus, primary, Pun, Matthew, primary, Deogharkar, Akash, primary, Chung, Chan, primary, Tarapore, Rohinton S., primary, Ramage, Samuel, primary, Chi, Andrew, primary, Wen, Patrick Y., primary, Arrillaga-Romany, Isabel, primary, Batchelor, Tracy T., primary, Butowski, Nicholas A., primary, Sumrall, Ashley, primary, Shonka, Nicole, primary, Harrison, Rebecca A., primary, de Groot, John, primary, Mehta, Minesh, primary, Hall, Matthew D., primary, Daghistani, Doured, primary, Cloughesy, Timothy F., primary, Ellingson, Benjamin M., primary, Beccaria, Kevin, primary, Varlet, Pascale, primary, Kim, Michelle M., primary, Umemura, Yoshie, primary, Garton, Hugh, primary, Franson, Andrea, primary, Schwartz, Jonathan, primary, Jain, Rajan, primary, Kachman, Maureen, primary, Baum, Heidi, primary, Burant, Charles F., primary, Mottl, Sophie L., primary, Cartaxo, Rodrigo T., primary, John, Vishal, primary, Messinger, Dana, primary, Qin, Tingting, primary, Peterson, Erik, primary, Sajjakulnukit, Peter, primary, Ravi, Karthik, primary, Waugh, Alyssa, primary, Walling, Dustin, primary, Ding, Yujie, primary, Xia, Ziyun, primary, Schwendeman, Anna, primary, Hawes, Debra, primary, Yang, Fusheng, primary, Judkins, Alexander R., primary, Wahl, Daniel, primary, Lyssiotis, Costas A., primary, de la Nava, Daniel, primary, Alonso, Marta M., primary, Eze, Augustine, primary, Spitzer, Jasper, primary, Schmidt, Susanne V., primary, Duchatel, Ryan J., primary, Dun, Matthew D., primary, Cain, Jason E., primary, Jiang, Li, primary, Stopka, Sylwia A., primary, Baquer, Gerard, primary, Regan, Michael S., primary, Filbin, Mariella G., primary, Agar, Nathalie Y.R., primary, Zhao, Lili, primary, Kumar-Sinha, Chandan, primary, Mody, Rajen, primary, Chinnaiyan, Arul, primary, Kurokawa, Ryo, primary, Pratt, Drew, primary, Yadav, Viveka N., primary, Grill, Jacques, primary, Kline, Cassie, primary, Mueller, Sabine, primary, Resnick, Adam, primary, Nazarian, Javad, primary, Allen, Joshua E., primary, Odia, Yazmin, primary, Gardner, Sharon L., primary, and Koschmann, Carl, primary

Published
2023
Full Text
View/download PDF

29. Data from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Author

Venneti, Sriram, primary, Kawakibi, Abed Rahman, primary, Ji, Sunjong, primary, Waszak, Sebastian M., primary, Sweha, Stefan R., primary, Mota, Mateus, primary, Pun, Matthew, primary, Deogharkar, Akash, primary, Chung, Chan, primary, Tarapore, Rohinton S., primary, Ramage, Samuel, primary, Chi, Andrew, primary, Wen, Patrick Y., primary, Arrillaga-Romany, Isabel, primary, Batchelor, Tracy T., primary, Butowski, Nicholas A., primary, Sumrall, Ashley, primary, Shonka, Nicole, primary, Harrison, Rebecca A., primary, de Groot, John, primary, Mehta, Minesh, primary, Hall, Matthew D., primary, Daghistani, Doured, primary, Cloughesy, Timothy F., primary, Ellingson, Benjamin M., primary, Beccaria, Kevin, primary, Varlet, Pascale, primary, Kim, Michelle M., primary, Umemura, Yoshie, primary, Garton, Hugh, primary, Franson, Andrea, primary, Schwartz, Jonathan, primary, Jain, Rajan, primary, Kachman, Maureen, primary, Baum, Heidi, primary, Burant, Charles F., primary, Mottl, Sophie L., primary, Cartaxo, Rodrigo T., primary, John, Vishal, primary, Messinger, Dana, primary, Qin, Tingting, primary, Peterson, Erik, primary, Sajjakulnukit, Peter, primary, Ravi, Karthik, primary, Waugh, Alyssa, primary, Walling, Dustin, primary, Ding, Yujie, primary, Xia, Ziyun, primary, Schwendeman, Anna, primary, Hawes, Debra, primary, Yang, Fusheng, primary, Judkins, Alexander R., primary, Wahl, Daniel, primary, Lyssiotis, Costas A., primary, de la Nava, Daniel, primary, Alonso, Marta M., primary, Eze, Augustine, primary, Spitzer, Jasper, primary, Schmidt, Susanne V., primary, Duchatel, Ryan J., primary, Dun, Matthew D., primary, Cain, Jason E., primary, Jiang, Li, primary, Stopka, Sylwia A., primary, Baquer, Gerard, primary, Regan, Michael S., primary, Filbin, Mariella G., primary, Agar, Nathalie Y.R., primary, Zhao, Lili, primary, Kumar-Sinha, Chandan, primary, Mody, Rajen, primary, Chinnaiyan, Arul, primary, Kurokawa, Ryo, primary, Pratt, Drew, primary, Yadav, Viveka N., primary, Grill, Jacques, primary, Kline, Cassie, primary, Mueller, Sabine, primary, Resnick, Adam, primary, Nazarian, Javad, primary, Allen, Joshua E., primary, Odia, Yazmin, primary, Gardner, Sharon L., primary, and Koschmann, Carl, primary

Published
2023
Full Text
View/download PDF

32. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

Author

Chi, Andrew S., Tarapore, Rohinton S., Hall, Matthew D., Shonka, Nicole, Gardner, Sharon, Umemura, Yoshie, Sumrall, Ashley, Khatib, Ziad, Mueller, Sabine, Kline, Cassie, Zaky, Wafik, Khatua, Soumen, Weathers, Shiao-Pei, Odia, Yazmin, Niazi, Toba N., Daghistani, Doured, Cherrick, Irene, Korones, David, Karajannis, Matthias A., Kong, Xiao-Tang, Minturn, Jane, Waanders, Angela, Arillaga-Romany, Isabel, Batchelor, Tracy, Wen, Patrick Y., Merdinger, Krystal, Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, and Mehta, Minesh P.

Published
2019
Full Text
View/download PDF

33. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Author

Venneti, Sriram, primary, Kawakibi, Abed Rahman, additional, Ji, Sunjong, additional, Waszak, Sebastian M., additional, Sweha, Stefan R., additional, Mota, Mateus, additional, Pun, Matthew, additional, Deogharkar, Akash, additional, Chung, Chan, additional, Tarapore, Rohinton S., additional, Ramage, Samuel, additional, Chi, Andrew, additional, Wen, Patrick Y., additional, Arrillaga-Romany, Isabel, additional, Batchelor, Tracy T., additional, Butowski, Nicholas A., additional, Sumrall, Ashley, additional, Shonka, Nicole, additional, Harrison, Rebecca A., additional, de Groot, John, additional, Mehta, Minesh, additional, Hall, Matthew D., additional, Daghistani, Doured, additional, Cloughesy, Timothy F., additional, Ellingson, Benjamin M., additional, Beccaria, Kevin, additional, Varlet, Pascale, additional, Kim, Michelle M., additional, Umemura, Yoshie, additional, Garton, Hugh, additional, Franson, Andrea, additional, Schwartz, Jonathan, additional, Jain, Rajan, additional, Kachman, Maureen, additional, Baum, Heidi, additional, Burant, Charles F., additional, Mottl, Sophie L., additional, Cartaxo, Rodrigo T., additional, John, Vishal, additional, Messinger, Dana, additional, Qin, Tingting, additional, Peterson, Erik, additional, Sajjakulnukit, Peter, additional, Ravi, Karthik, additional, Waugh, Alyssa, additional, Walling, Dustin, additional, Ding, Yujie, additional, Xia, Ziyun, additional, Schwendeman, Anna, additional, Hawes, Debra, additional, Yang, Fusheng, additional, Judkins, Alexander R., additional, Wahl, Daniel, additional, Lyssiotis, Costas A., additional, de la Nava, Daniel, additional, Alonso, Marta M., additional, Eze, Augustine, additional, Spitzer, Jasper, additional, Schmidt, Susanne V., additional, Duchatel, Ryan J., additional, Dun, Matthew D., additional, Cain, Jason E., additional, Jiang, Li, additional, Stopka, Sylwia A., additional, Baquer, Gerard, additional, Regan, Michael S., additional, Filbin, Mariella G., additional, Agar, Nathalie Y.R., additional, Zhao, Lili, additional, Kumar-Sinha, Chandan, additional, Mody, Rajen, additional, Chinnaiyan, Arul, additional, Kurokawa, Ryo, additional, Pratt, Drew, additional, Yadav, Viveka N., additional, Grill, Jacques, additional, Kline, Cassie, additional, Mueller, Sabine, additional, Resnick, Adam, additional, Nazarian, Javad, additional, Allen, Joshua E., additional, Odia, Yazmin, additional, Gardner, Sharon L., additional, and Koschmann, Carl, additional

Published
2023
Full Text
View/download PDF

34. TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

Author

Arrillaga-Romany, Isabel, primary, Lassman, Andrew, additional, McGovern, Susan, additional, Mueller, Sabine, additional, Nabors, Louis Burt, additional, van den Bent, Martin, additional, Vogelbaum, Michael, additional, Allen, Joshua E, additional, Melemed, Allen S, additional, Tarapore, Rohinton, additional, Wen, Patrick, additional, and Cloughsey, Timothy, additional

Published
2023
Full Text
View/download PDF

36. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer

Author

Paraghamian, Sarah E., primary, Qiu, Jianqing, additional, Hawkins, Gabrielle M., additional, Zhao, Ziyi, additional, Sun, Wenchuan, additional, Fan, Yali, additional, Zhang, Xin, additional, Suo, Hongyan, additional, Hao, Tianran, additional, Prabhu, Varun Vijay, additional, Allen, Joshua E., additional, Zhou, Chunxiao, additional, and Bae-Jump, Victoria, additional

Published
2023
Full Text
View/download PDF

37. Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Author

Arrillaga-Romany, Isabel, primary, Lassman, Andrew, additional, McGovern, Susan L., additional, Mueller, Sabine, additional, Nabors, Louis B., additional, van den Bent, Martin, additional, Vogelbaum, Michael, additional, Allen, Joshua E., additional, Melemed, Allen S., additional, Tarapore, Rohinton S., additional, Yang, Dewen, additional, Wen, Patrick, additional, and Cloughsey, Timothy, additional

Published
2023
Full Text
View/download PDF

38. Abstract 4659: Depicting ONC201/Delta-24-RGD combination for the treatment of pHGGs and DMGs reveals a therapeutic benefit and a proinflammatory tumor microenvironment remodelation

Author

de la Nava, Daniel, primary, Laspidea, Virginia, additional, Ausejo-Mauleón, Iker, additional, García-Moure, Marc, additional, Mueller, Sabine, additional, Nazarian, Javad, additional, Allen, Joshua E., additional, Becher, Oren, additional, Fueyo, Juan, additional, Gomez-Manzano, Candelaria, additional, Patiño-Garcia, Ana, additional, Koschmann, Carl, additional, and Alonso, Marta M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results